Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Global Metabolomics Services Market Trends and Forecast Report 2022-2035, Featuring Profiles of Creative Proteomics, DNA Xperts, Metabo Profile, Metabolon and Synbio Technologies
Company Logo
Company Logo

Dublin, May 11, 2022 (GLOBE NEWSWIRE) -- The "Metabolomics Services Market by Area of Application, Type of Metabolomics Service Offered, Type of Metabolome Profiling Technique Used, Type of End User and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Since the initiation of the Human Metabolome Project in 2005, the metabolomics technique has gathered significant attention from the industry stakeholders. It is worth mentioning that about 40,000 small molecules constitute the human metabolome. Further, 30% of the known genetic disorders are associated with small-molecule metabolism. Therefore, metabolome profiling can assist in obtaining a better understanding of the disease. The approach has also demonstrated to be capable of identifying new biomarkers and novel drug targets. In fact, 50% of the total drug candidates are reported to emanate from pre-existing metabolites.

Integration of metabolomics with development projects holds the potential to significantly improve the efficiency and success rate of drug discovery, owing to its ability to differentiate promising candidates in the early stages. As a result, metabolomics has become an indispensable part of modern drug discovery and development process and disease diagnosis. Further, with the growing prominence of personalized medicine, there is an increased demand for rapid, highly sensitive and accurate quantification methods, such as metabolomics, to analyze clinical specimens. It is worth highlighting that various types of metabolite detection techniques, including targeted metabolomics and untargeted metabolomics, are being employed for diagnosis, severity determination and therapy development efforts against COVID-19. Specifically, studies have reported the potential implications of the serum metabolome in understanding the pathophysiology of the aforementioned disease.

Given the growing pipeline of biomarkers and drug discovery projects, the current demand for metabolite profiling is high. In this context, more than 18,000 drug candidates are being evaluated across different development stages, at present. Although some pharmaceutical companies have established in-house metabolomics research capabilities, significant capital investments and specialized requirements render this approach prohibitive for most stakeholders. Moreover, the associated metabolomics technologies, including chromatography and spectrometry, are complicated by multi-step analytical protocols and technically demanding expertise, which eventually leads to contamination of samples and lack of reproducibility in test results. This has created a demand for service providers having the required expertise in the global metabolomics market.